AML-126: Prognostic Value of Serum CD 155 in Adult Acute Myeloid Leukemia Patients: Relation to Clinical Outcome

Azzazi, Mohamed; Hegab, Hany M.; Abdelallah, Nour EL-Hoda; Mohamed, Haydi

doi:10.1016/s2152-2650(20)30717-5

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to its immunological functions, CD155 also functions in cellular differentiation, proliferation, survival, and adhesion [ 223 ]. As shown by recent studies, CD155 was considerably higher in patients with AML in comparison with the control cases, and it appears that there is an association with a poor prognosis [ 224 ]. In spite of CD155's normal expression on hematopoietic cells, it has an immunosuppressive role and a dual function in tumor immunity.…”

Section: Immune Checkpoints’ Roles In Aml Angiogenesis Metastasis And...mentioning

confidence: 96%

The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways

Bakhtiyari,

Liaghat,

Aziziyan

et al. 2023

Cell Commun Signal

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) comprises a multifarious and heterogeneous array of illnesses characterized by the anomalous proliferation of myeloid cells in the bone marrow microenvironment (BMM). The BMM plays a pivotal role in promoting AML progression, angiogenesis, and metastasis. The immune checkpoints (ICs) and metabolic processes are the key players in this process. In this review, we delineate the metabolic and immune checkpoint characteristics of the AML BMM, with a focus on the roles of BMM cells e.g. tumor-associated macrophages, natural killer cells, dendritic cells, metabolic profiles and related signaling pathways. We also discuss the signaling pathways stimulated in AML cells by BMM factors that lead to AML progression. We then delve into the roles of immune checkpoints in AML angiogenesis, metastasis, and cell proliferation, including co-stimulatory and inhibitory ICs. Lastly, we discuss the potential therapeutic approaches and future directions for AML treatment, emphasizing the potential of targeting metabolic and immune checkpoints in AML BMM as prognostic and therapeutic targets. In conclusion, the modulation of these processes through the use of directed drugs opens up new promising avenues in combating AML. Thereby, a comprehensive elucidation of the significance of these AML BMM cells' metabolic and immune checkpoints and signaling pathways on leukemic cells can be undertaken in the future investigations. Additionally, these checkpoints and cells should be considered plausible multi-targeted therapies for AML in combination with other conventional treatments in AML.

show abstract

Section: Immune Checkpoints’ Roles In Aml Angiogenesis Metastasis And...mentioning

confidence: 96%

The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways

Bakhtiyari,

Liaghat,

Aziziyan

et al. 2023

Cell Commun Signal

View full text Add to dashboard Cite

show abstract

PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma

et al. 2022

View full text Add to dashboard Cite

Poliovirus receptor (PVR, CD155) is upregulated during tumor progression, and PVR expression is associated with poor prognosis in cancer patients; however, prognostic implications for PVR in multiple myeloma (MM) have not been investigated. PVR plays an immunomodulatory role by interacting with CD226, CD96, and TIGIT. TIGIT is a checkpoint inhibitory receptor that can limit adaptive and innate immunity, and it binds to PVR with the highest affinity. We used immunohistochemistry, ELISA, qPCR, and flow cytometry to investigate the role of PVR in MM. PVR was highly expressed in patients with MM, and membrane PVR expression showed a significant correlation with soluble PVR levels. PVR expression was significantly associated with the Revised-International Staging System stage, presence of extramedullary plasmacytoma and bone lesion, percentage of bone marrow plasma cells (BMPCs), and β2-microglobulin levels, suggesting a possible role in advanced stages and metastasis. Furthermore, TIGIT expression was significantly correlated with the percentage of BMPCs. Patients with high PVR expression had significantly shorter overall and progression-free survival, and PVR expression was identified as an independent prognostic factor for poor MM survival. These findings indicate that PVR expression is associated with MM stage and poor prognosis, and is a potential prognostic marker for MM.

show abstract

Clinical significance of serum CD155 levels in acute lymphoblastic leukemia patients

Ibrahim Ibrahim,

Osman Mostafa,

Azzazi

et al. 2023

EGJH

View full text Add to dashboard Cite

Background Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by poor outcomes in adults. Traditional diagnostic and prognostic markers take into account clinical data but also rely heavily on expensive and invasive tests such as bone marrow studies with cytogenetics. CD155 is an adhesion molecule that also modulates immune response in malignancy. Previous studies have shown that serum CD155 (sCD155) levels are higher in patients with malignancies, and have demonstrated a correlation between higher levels of sCD155 and poor outcomes. This study investigated the diagnostic and prognostic value of sCD155 in adult patients with acute lymphoblastic leukemia. Methodology 32 adult patients with acute lymphoblastic leukemia and 15 control patients were enrolled in this study. Clinical and outcome data were collected from patients and a blood sample from patients and controls was collected with ELISA testing for sCD155 levels. Results sCD155 was found to be significantly higher in patients than controls (P<0.05) and was significantly associated with bone marrow aspirate blast count. It was not associated with other clinical parameters including Sex, age, initial CBC parameter counts, presence of lymphadenopathy, presence of CNS infiltration, presence of Philadelphia chromosome, type of ALL, or risk stratification of ALL besides being associated with hepatosplenomegaly. ROC curve showed high sensitivity and specificity of sCD155 and Kaplan Meir curve showed a trend towards worse outcomes in patients with high sCD155 but it was not statistically significant. Conclusion sCD155 remains a promising marker for diagnosis of ALL but further studies are needed to confirm prognostic value.

show abstract

AML-126: Prognostic Value of Serum CD 155 in Adult Acute Myeloid Leukemia Patients: Relation to Clinical Outcome

Cited by 3 publications

References 0 publications

The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways

The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways

PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma

Clinical significance of serum CD155 levels in acute lymphoblastic leukemia patients

Contact Info

Product

Resources

About